البلد: كندا
اللغة: الإنجليزية
المصدر: Health Canada
MINOXIDIL
LABORATOIRE RIVA INC.
D11AX01
MINOXIDIL, TOPICAL
20MG
SOLUTION
MINOXIDIL 20MG
TOPICAL
250ML
OTC
MISC. SKIN AND MUCOUS MEMBRANE AGENTS
Active ingredient group (AIG) number: 0114429001; AHFS:
APPROVED
2022-09-29
_MINOX (Minoxidil Topical Solution) _ _Page 1 of 33_ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION MINOX Minoxidil Topical Solution 20 mg/mL (2% w/v) USP Hair Regrowth Treatment THIS PRODUCT IS FOR MEN ONLY LABORATOIRE RIVA INC. 660 Boul. Industriel Blainville, Quebec J7C 3V4 www.labriva.com Date of Initial Authorization: August 19, 1996 Date of Revision: August 4, 2022 Submission Control Number: 263345 _MINOX (Minoxidil Topical Solution) _ _Page 2 of 33_ TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED . TABLE OF CONTENTS .............................................................................................................. 2 PART I: HEALTH PROFESSIONAL INFORMATION ..................................................................... 4 1 INDICATIONS .............................................................................................................. 4 1.1 Pediatrics .......................................................................................................... 4 1.2 Geriatrics........................................................................................................... 4 2 CONTRAINDICATIONS ................................................................................................. 4 4 DOSAGE AND ADMINISTRATION................................................................................. 5 4.1 Dosing Considerations ....................................................................................... 5 4.2 Recommended Dose and Dosage Adjustment..................................................... 5 4.4 Administration................................................................................................... 5 4.5 Missed Dose ...................................................................................................... 6 5 OVERDOSAGE ............................................................................................................. 6 6 DOSAGE FORMS, STRENGTHS, COMPOSI اقرأ الوثيقة كاملة